New antibiotics to treat infections caused by drug-resistant Acinetobacter baumannii
Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections
This study is working on creating new antibiotics to help treat tough infections caused by a bacteria called Acinetobacter baumannii, which is hard to kill with current medicines, so it could really help patients who are struggling with these stubborn infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Notre Dame NIH-funded |
| Lab location | 1 site (Notre Dame, United States) |
| Project ID | NIH-11064768 on NIH RePORTER |
What this research studies
This research focuses on developing new carbapenem antibiotics to effectively treat infections caused by Acinetobacter baumannii, a bacterium known for its high resistance to existing antibiotics. The study aims to understand the mechanisms behind this resistance and create novel antibiotics that can overcome these challenges. By characterizing the enzymes that inactivate current treatments, the researchers hope to design drugs that can effectively target and eliminate these resistant bacteria. Patients suffering from infections caused by multidrug-resistant A. baumannii may benefit from the outcomes of this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with infections caused by carbapenem-resistant or multidrug-resistant Acinetobacter baumannii.
Not a fit: Patients with infections caused by bacteria that are not resistant to antibiotics or those with other unrelated infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients suffering from severe infections caused by multidrug-resistant bacteria.
How similar studies have performed: Other research has shown promise in developing new antibiotics targeting resistant bacteria, but this specific approach is novel and aims to address a critical gap in treatment options.
Where this research is happening
Notre Dame, United States
- University of Notre Dame — Notre Dame, United States (Active)
Researchers
- Principal investigator: Vakulenko, Sergei — University of Notre Dame
- Study coordinator: Vakulenko, Sergei
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.